<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776096</url>
  </required_header>
  <id_info>
    <org_study_id>ANTILERG001-19</org_study_id>
    <nct_id>NCT04776096</nct_id>
  </id_info>
  <brief_title>Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment</brief_title>
  <official_title>PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROLLED,60 DAYS, PARALLEL GROUPS, SUPERIORITY STUDY, TO COMPARE THE EFFECTIVENESS AND TOXICITY OF BEPOTASTINE 1.5% PF vs. OLOPATADINE 0.2% WITH BAK IN TREATMENT OF ALLERGIC CONJUNCTIVITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Poen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Poen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be carried out to evaluate the antiallergic efficacy of Bepotastine&#xD;
      besilate 1.5% free of preservatives versus standard treatment with 0.2% Olopatadine&#xD;
      hydrochloride with 0.1% benzalkonium chloride as preservative in adult patients diagnosed&#xD;
      with allergic conjunctivitis.&#xD;
&#xD;
      The antiallergic efficacy will be evaluated by the reduction of ocular signs and symptoms and&#xD;
      by the resolution of non-ocular symptoms (rhinorrhea, congestion, and nasal pruritus), as&#xD;
      well as the effect of the preservative and its relationship with the cytotoxicity of the&#xD;
      ocular surface. Also will evaluate the safety of both products.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MULTICENTRIC, DOUBLE BLIND, RANDOMIZED, CONTROLLED, 60 DAYS, GROUP PARALLEL GROUPS, TO SHOW SUPERIORITY.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Change of 1 point of scale 0-3 (none, mild, moderate, severe) in at least 1 visit between gruops.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eye burning</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye lacrimation</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foreign body sensation</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal congestion</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal pruritus</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid swelling</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Baseline and Day 60</time_frame>
    <description>Improve from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meniscus height</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye discharge</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60</time_frame>
    <description>Differences between treatments. Scale 0-3 (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjuctival impression cytology</measure>
    <time_frame>Baseline, Day 30, Day 60</time_frame>
    <description>Differences between treatments. Nelson classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 45, Day 60.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bepotastine besilate 1,5% preservative free</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine hydrochloride 0,2% with BAK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine Besilate 1.5% PF</intervention_name>
    <description>Bepotastine besilate 1,5% Preservative free ophthalmic solution</description>
    <arm_group_label>Bepotastine besilate 1,5% preservative free</arm_group_label>
    <other_name>TRALER LC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine Hydrochloride 0.2% BAK</intervention_name>
    <description>Olopatadine hydrochloride 0.2% with BAK as preservative</description>
    <arm_group_label>Olopatadine hydrochloride 0,2% with BAK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years old.&#xD;
&#xD;
          -  Clinical diagnosis of allergic conjunctivitis and active allergy with at least 2&#xD;
             points on itching and hyperemia scale.&#xD;
&#xD;
          -  Patients with history of allergic conjunctivitis.&#xD;
&#xD;
          -  Patients who accept no to wear contact lens during the duration of the trial.&#xD;
&#xD;
          -  Patients who accept no to use any other medication by any delivery route.&#xD;
&#xD;
          -  Patients with intraocular pressure controlled (less than 18 mmhg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have undergone refractive surgery within the 6 months prior to the start&#xD;
             of the study&#xD;
&#xD;
          -  Patient with ocular or systemic active diseases&#xD;
&#xD;
          -  Patients who are participating in another trial&#xD;
&#xD;
          -  Patients who have used eye medication in the last 15 days and/or who have received&#xD;
             anti-inflammatory drugs (corticosteroids and/or NSAIDs) and/or antihistamines by mouth&#xD;
             or intravenous.&#xD;
&#xD;
          -  Patients hypersensitive to any component of the products: Bepotastine besilate, sodium&#xD;
             chloride, monosodium phosphate dihydrate, sodium hydroxide, Olopatadine hydrochloride,&#xD;
             benzalkonium chloride, dibasic sodium phosphate, hydrochloric acid, edetate disodium&#xD;
             or povidone K29 / 32.&#xD;
&#xD;
          -  Women who are breastfeeding and pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melina del Papa</last_name>
    <phone>+54 15 6048 0067</phone>
    <email>mdelpapa@poen.net.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Passerini</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Alta Complejidad El Cruce - Nestor Kirchner</name>
      <address>
        <city>Caba</city>
        <zip>B1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Marini</last_name>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Marini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucía</name>
      <address>
        <city>Caba</city>
        <zip>C1232AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Moreno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cecilia Moreno Arbeleche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Albera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Pedro Lagleyze</name>
      <address>
        <city>Caba</city>
        <zip>C1416 DJI</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Berra</last_name>
    </contact>
    <investigator>
      <last_name>Martin Berra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belén Ortiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>jULIETA Geraldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Churruca - Visca</name>
      <address>
        <city>Caba</city>
        <zip>C1437</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Girado</last_name>
    </contact>
    <investigator>
      <last_name>Fernanda Girado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Masenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliana Paino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Bepotastine besilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

